281 completed, 110 recruiting, 110 terminated, 44 unknown. 625 Phase 1, 210 Phase 2.
Follow Ovarian Cancer: new trials by email Literature Review of Ovarian Cancer trials Research Report on Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Phase 1 Study of VT-101 in Advanced Ovarian Cancer VT-101 - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 1 | Not yet recruiting | Michael J. Goodheart | 22 | 2026-10-23 | 2026-10-29 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. YF550 - Solid Tumor (Phase I), Ovarian Cancer | Phase 1 | Not yet recruiting | InventisBio Yiqi Beijing Limited | 204 | 2026-10-01 | 2026-10-26 |
| A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. TJ102 - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Phrontline Biopharma | 150 | 2026-09-29 | 2026-10-21 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 130 | 2026-09-14 | 2026-10-16 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery Low Dose, middle dose, high dose - Ovarian Cancer, mRNA Vaccine | Phase 1 | Recruiting | West China Hospital | 9 | 2026-09-10 | 2026-09-09 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery Low Dose NeoOVIV, Medium dose NeoOVIV, High dose NeoOVIV - Ovarian Cancer, mRNA Vaccine | Phase 1 | Recruiting | West China Hospital | 9 | 2026-09-10 | 2026-09-09 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors TS-104 - NSCLC (Non-small Cell Lung Cancer), HNSCC | Phase 1 | Recruiting | TwoStep Therapeutics, Inc. | 74 | 2026-09-02 | 2026-09-30 |
| Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CryptiVax-1001 - Ovarian Cancer, HGSOC | Phase 1 | Recruiting | Epitopea Ltd | 50 | 2026-09-01 | 2026-10-16 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer Ubamatamab, Chemotherapy, Bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 43 | 2026-08-01 | 2026-07-10 |
| Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. ARR-002 - Ovarian Cancer, Endometrial Cancer | Phase 1 | Recruiting | ArriVent BioPharma, Inc. | 180 | 2026-07-23 | 2026-09-03 |
| Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors RGT-490 - Breast Cancer, Ovarian Cancer | Phase 1 | Recruiting | Regor Pharmaceuticals Inc. | 63 | 2026-07-21 | 2026-11-02 |
| A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. OPB-201 - Endometrial Cancer Recurrent, Endometrial Cancer | Phase 1 | Recruiting | Outpace Bio, Inc. | 30 | 2026-06-30 | 2026-10-26 |
| Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors XmAb541, XmAb808 - Ovarian Cancer | Phase 1 | Recruiting | Xencor, Inc. | 90 | 2026-06-30 | 2026-08-13 |
| Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer? Normethermic Intraperitoneal Chemotherapy with carboplatin - Ovarian Cancer | Phase 1 | Recruiting | Odense University Hospital | 10 | 2026-06-16 | 2026-07-29 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CKD-215, D215 - Ovarian Cancer | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 24 | 2026-06-01 | 2026-04-15 |
Showing 20 of 625. Sign in to see all of them.
Ovarian Neoplasms (625) · Breast Neoplasms (178) · Carcinoma, Non-Small-Cell Lung (133) · Fallopian Tube Neoplasms (111) · Endometrial Neoplasms (104) · Carcinoma, Ovarian Epithelial (102) · Colorectal Neoplasms (99) · Pancreatic Neoplasms (95) · Stomach Neoplasms (86) · Lung Neoplasms (81) · Uterine Cervical Neoplasms (75) · Prostatic Neoplasms (67) · Triple Negative Breast Neoplasms (67) · Melanoma (63) · Neoplasm Metastasis (60)
Adnexal Diseases (625) · Endocrine Gland Neoplasms (625) · Endocrine System Diseases (625) · Female Urogenital Diseases (625) · Female Urogenital Diseases and Pregnancy Complications (625) · Genital Diseases (625) · Genital Diseases, Female (625) · Gonadal Disorders (625) · Urogenital Diseases (625) · Genital Neoplasms, Female (624) · Neoplasms by Site (624) · Ovarian Diseases (622) · Urogenital Neoplasms (622) · Neoplasms (568) · Neoplasms by Histologic Type (301)
Carboplatin (68) · Paclitaxel (65) · pembrolizumab (33) · Cyclophosphamide (32) · Bevacizumab (30) · Topotecan (28) · liposomal doxorubicin (22) · Cisplatin (21) · Gemcitabine (21) · Filgrastim (20) · olaparib (18) · Docetaxel (17) · Peripheral Blood Stem Cell Transplantation (17) · fludarabine (16) · niraparib (13)
National Cancer Institute (NCI) (21) · Memorial Sloan Kettering Cancer Center (18) · M.D. Anderson Cancer Center (12) · AstraZeneca (9) · Masonic Cancer Center, University of Minnesota (9) · Gynecologic Oncology Group (8) · Ludwig Institute for Cancer Research (8) · Pfizer (7) · AbbVie (6) · Dana-Farber Cancer Institute (6) · Incyte Corporation (6) · University of Alabama at Birmingham (6) · Celldex Therapeutics (5) · Chongqing Precision Biotech Co., Ltd (5) · City of Hope Medical Center (5)
United States (434) · China (69) · Spain (48) · Australia (46) · United Kingdom (46) · Canada (39) · France (28) · Belgium (23) · Netherlands (19) · South Korea (19) · Italy (16) · Japan (15) · Germany (14) · Israel (13) · Denmark (12)
Paul Sabbatini, MD (6) · Daniela Matei, M.D. (3) · Leona A. Holmberg, MD, PhD (3) · Levi S. Downs, MD (3) · Peter G. Rose, MD (3) · Amir Jazaeri, MD (2) · Angeles A Secord, MD (2)
PMID 16394300, PMID 36459691, PMID 40443562, PMID 11181662, PMID 11410496, PMID 11705489, PMID 12082455, PMID 12082456, PMID 12114401, PMID 12528778, PMID 12957454, PMID 14751144, PMID 14767498, PMID 15010069, PMID 15033677, PMID 15131031, PMID 15592836, PMID 16135465, PMID 16150481, PMID 16234526, PMID 16368439, PMID 16412499, PMID 16626792, PMID 16631245, PMID 16914576, PMID 16959305, PMID 17194908, PMID 17910981, PMID 18191187, PMID 18245546, PMID 18281544, PMID 18327587, PMID 18451240, PMID 18483372, PMID 18692224, PMID 19075272, PMID 19088049, PMID 19427025, PMID 19430790, PMID 19460658, PMID 19648970, PMID 19671873, PMID 19706807, PMID 20022092, PMID 20044751, PMID 20194867, PMID 20407240, PMID 20460632, PMID 20564122, PMID 20818904
2018 (8), 2023 (6), 2017 (5), 2025 (4), P30CA033572 (4), 2015 (3), P01CA111412 (3), 2008 (2), 2009 (2), 2016 (2), 2019 (2), P30CA015083 (2), P30CA023074 (2), P30CA043703 (2), P50CA083639 (2)